|
Copanlisib treatment in patients with relapsed or refractory indolent B-cell lymphoma: Subgroup analyses of diabetic patients from the phase II CHRONOS-1 study. |
|
|
Honoraria - Bayer; Celgene; Gilead Sciences; Janssen; Roche |
Consulting or Advisory Role - Bayer; Celgene; Gilead Sciences; Janssen; Mundipharma; Roche; Sandoz |
|
|
|
Consulting or Advisory Role - Celgene; Janssen; Roche; Takeda |
Research Funding - Bayer; Janssen; Roche; Takeda |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |